Factors associated with treatment response in patients with idiopathic inflammatory myopathies. A registry-based study.

Patients with DM-specific autoantibodies achieved better levels of response compared to other autoantibody-defined groups. Dysphagia, shorter time span from symptom onset to diagnosis and intensive initial immunosuppressive treatment were associated with a higher response rate after one year of pharmacological treatment from the index date, regardless of autoantibody status.